Abbott Laboratories | ABT.USX
United States - USD

Stock Exchange: NYSE

Symbol: ABT

Sector: Healthcare

Industry: Medical Devices

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Abbott Laboratories Stats

Previous close:Daily change:
117.13-1.02%
52-Week High:52-Week Low:
121.6499.71
Market Cap:Beta:
201.1 Billion0.72

Abbott Laboratories Key Financials

P/E Ratio:Revenues:Revenue Growth:Gross Margin:
35.237141.2 Billion4.90%55.91%
Dividend Yield:Net Income:Earnings Growth:Net Income Margin:
1.88%5.7 Billion14.60%13.99%
P/E Ratio:Revenues:
35.237141.2 Billion
Dividend Yield:Net Income:
1.88%5.7 Billion
Revenue Growth:Gross Margin:
4.90%55.91%
Earnings Growth:Net Income Margin:
14.60%13.99%
ParametersStocks Investing
Stock CurrencyUSD
Dividend PayingYes
Fractional SharesNo
Maximum Shares100 Shares
Tick value per 1 share0.01 USD
Trading Commission0%
Minimum Price Increment0.01
Limit and Stop Levels0.0
Negative balance protectionNo
Swap free days allowanceN/A
Own the underlying AssetNo
Platform symbolABT.USX
Disclaimer: This material is provided by third-party data sources as a general marketing communication for information purposes only and does not constitute an independent investment research. Nothing in this communication contains, or should be considered as containing, an investment advice or an investment recommendation or a solicitation for the purpose of buying or selling of any financial instrument. All information provided is gathered from reputable sources and any information containing an indication of past performance is not a guarantee or reliable indicator of future performance. Users acknowledge that any investment in CFDs and Physical Stocks products is characterized by a certain degree of uncertainty and that any investment of this nature involves a high level of risk for which the users are solely responsible and liable. We assume no liability for any loss arising from any investment made based on the information presented here.
Avertissement relatif aux investissements à haut risque : les contrats de différence (« CFD ») sont des produits financiers complexes qui se négocient sur marge. Les opérations sur les CFD sont assorties d'un niveau de risque élevé. Vous risquez de perdre la totalité de votre capital. Ces produits sont susceptibles de ne pas être adaptés à tout le monde et il convient de vous assurer de bien comprendre les risques encourus. Si nécessaire, sollicitez l'avis d'un expert indépendant et n'investissez que des fonds dont vous pouvez assumer la perte. Nous vous invitons à réfléchir mûrement à la pertinence de ce type d'opérations, au regard de l'ensemble des circonstances pertinentes et de vos ressources personnelles. Nous déconseillons aux clients de mobiliser la totalité du solde de leur compte en vue de satisfaire aux exigences de marge. Les clients ont la possibilité de minimiser leur niveau d'exposition en demandant une modification du plafond de l'effet de levier. Pour obtenir de plus amples informations, veuillez vous reporter au document de divulgation des risques de HYCM.
Avis de non-responsabilité : Le contenu de cette page sert un propos purement informatif et n'a pas valeur de recommandation ou de conseil. Toute indication de performance passée ou simulation sur la base de performance passée incluse dans les annonces publiées par HYCM n'est pas un indicateur fiable des résultats futurs. Le client assume l'entière responsabilité de toutes les transactions ou investissements qui sont effectués à HYCM.
Restrictions régionales : nous n'offrons pas nos services aux résidents de certaines juridictions telles que l'Afghanistan, la Belgique, Hong Kong, les États-Unis d'Amérique et d'autres régions. Pour obtenir davantage d'informations, veuillez consulter notre
Centre d'aide

HYCM Limited is authorized and regulated under the Dubai Financial Services Authority with license number F000048.

Copyright © 2024 HYCM.